The Jewish General Hospital Cell Processing Center (JGH CPC) at the Lady Davis Institute is designed as an enabling infrastructure to support the prosecution of early phase clinical trials of cell-based / derived therapies where processing of human cell and tissue is required as part of the study. The objective of this facility is to render accessible to the patient community cutting edge, experimental cellular pharmaceuticals for treatment of human catastrophic illnesses. It promotes development of technologies from institutional scientists as well as partnership development of technologies from other biomedical institutions, academic networks, biotechnology firms and pharmaceutical industry.
The facility comprises the Clean Room area (including SAS), as well as the Laboratory Annex supporting the Clean Room, and the adjacent mechanical room. The Clean Room is a clinical-grade, high sterility isolation facility previously certified ISO Class 7. It is operated by highly qualified personnel (Laboratory Director Dr. Nicoletta Eliopoulos, and Research Assistant Ms. Jing Zhao) with a track record of successful implementation and prosecution of custom autologous cellular pharmaceuticals, such as for the past preparation of eNOS-transfected endothelial progenitor cells for a Phase I clinical trial in patients with pulmonary hypertension (PHACeT trial). The current medical director of the JGH CPC is Dr. Lawrence Rosenberg.
The JGH CPC’s successful development is optimized within an environment of cooperation on a regional and national scale. The JGH CPC is part of the McGill family of enabling infrastructures and has established links with many Quebec-based Medical Schools. It is also developed as a biotech and pharmaceutical service contract facility.
Contact information:
Laboratory Director: Dr. Nicoletta Eliopoulos: (514)340-8222ext.22757 nicoletta.eliopoulos@mcgill.ca Research Assistant: Ms. Jing Zhao: (514)340-8222ext.25432
|